DQ113

Known as: D61-1113, DQ 113, DQ-113 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2002-2007
01220022007

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
DQ-113 was compared in vitro to sitafloxacin, moxifloxacin, levofloxacin, and ciprofloxacin for potential to select mutational… (More)
  • figure 1
  • table 1
  • table 2
Is this relevant?
2003
2003
A series of novel 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolones bearing fluorinated (3R)-3-(1… (More)
Is this relevant?
2003
2003
We compared the effects of DQ-113, a new quinolone, to those of vancomycin (VCM) and teicoplanin (TEIC) in murine models of… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
Is this relevant?
2003
2003
DQ-113 is a new quinolone with potent activity against gram-positive pathogens. The in vivo activity of DQ-113 against… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
Is this relevant?
2002
2002
The antibacterial activity of DQ-113, formerly D61-1113, was compared with those of antibacterial agents currently available… (More)
Is this relevant?
Review
2002
Review
2002
Multidrug resistant organisms such as MRSA, PRSP, BLNAR, ESBL-producing K. pneumoniae and VRE have in recent years emerged as… (More)
Is this relevant?